Raymond James Financial I... (RJF)
NYSE: RJF
· Real-Time Price · USD
170.27
3.71 (2.23%)
At close: Sep 04, 2025, 1:47 PM
2.23% (1D)
| Bid | 170.24 |
| Market Cap | 33.95B |
| Revenue (ttm) | 15.57B |
| Net Income (ttm) | 2.13B |
| EPS (ttm) | 10.19 |
| PE Ratio (ttm) | 16.71 |
| Forward PE | 14.4 |
| Analyst | Hold |
| Ask | 170.35 |
| Volume | 329,329 |
| Avg. Volume (20D) | 1,028,374 |
| Open | 167.59 |
| Previous Close | 166.56 |
| Day's Range | 167.20 - 170.28 |
| 52-Week Range | 113.91 - 174.32 |
| Beta | 1.06 |
Analyst Forecast
According to 0 analyst ratings, the average rating for RJF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Raymond James Financial Inc. is scheduled to release its earnings on
Oct 22, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+2.09%
Shares of banks and financial services stocks are ...
Unlock content with
Pro Subscription
3 months ago
+4.27%
Shares of banks and financial services stocks are higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A reduction in tariffs could alleviate macro uncertainty in the lending and deal environment.
1 month ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...
1 month ago · seekingalpha.com
Raymond James: Rising Markets Offset Cash Headwinds (Rating Upgrade)Raymond James Financial's fundamentals remain strong, with higher AUM and resilient net interest income despite recent earnings noise from a one-time legal reserve. Client cash outflows and potential ...
